News | October 07, 2010

Blood Pressure Pills More Effective When Taken at Night

October 7, 2010 - Taking medication at night instead of in the morning significantly increases efficacy in keeping blood pressure within a healthy range, according to a new study in Chronobiology International. Additionally, taking medication at night offers extra protection against heart attacks, strokes and other types of cardiovascular diseases.

Two articles in Chronobiology International, the international journal on how biological rhythms affect the systems of living things, cover the results of the MAPEC study.

Over the five-year study, the group of patients who took at least one of their medications at night experienced just one-third of the number of cardiovascular disease (CVD) episodes experienced by the group of patients who took all their medications in the morning.

"This study proves that the time of day when patients take their high blood pressure medications can make a huge difference due to the effect of the body's circadian rhythms on the actions of medications and because of the importance of preserving the normal day-night pattern of blood pressure in hypertension," said professor Ramón C. Hermida, Ph.D., director of bioengineering and chronobiology labs at the University of Vigo in Spain and lead investigator of the MAPEC Study. "Conventional treatment typically advises taking blood pressure medications in the morning. The MAPEC study shows that conventional treatment is not the most effective way to help patients with high blood pressure.”

Based on around-the-clock ambulatory blood pressure monitoring, the study found that taking at least one blood pressure medication at bedtime was best at normalizing sleep-time blood pressure. This is known to be the most sensitive predictor of a patient's five-year risk of CVD mortality. In addition, the study shows that taking medication at night is the best way to control daytime BP levels.

"Historically, medical professionals have operated on the assumption that sleep-time blood pressure levels will drop by 10 to 20 percent from daytime levels. However, for many patients – called nondippers – this doesn't happen and sleep-time therefore becomes a high risk period," said Francesco Portaluppi, M.D., of the Hypertension Center at the University Hospital of Ferrara in Italy and lead author of the perspectives article on the MAPEC study. "This study was the first to conclusively find that the time of day when medications are ingested not only affects efficacy but also CVD risk and these findings must fundamentally change the way patients are treated worldwide."

"Our body clocks are extremely powerful biological tools and this study offers insight and hard facts on how we can harness that power to help millions of people stay healthier and safer by ensuring that their blood pressure medications are taken as effectively as possible," said Michael Smolensky, editor of Chronobiology International.

More than 70 million people in the United States have hypertension.

For more information: www.informahealthcare.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init